Pharvaris Phase 3 trial once-daily deucrictibant XR cut HAE attack rates 83% vs placebo, supporting 1H27 NDA
Pharvaris Phase 3 CHAPTER-3 trial shows once-daily deucrictibant XR cut HAE attack rates 83% vs placebo, supporting 1H 2027 NDA and global filing plans
- CHAPTER-3 met its primary endpoint and all secondary endpoints in hereditary angioedema attack prophylaxis.
- Trial evaluated once-daily oral deucrictibant XR as prophylactic treatment for hereditary angioedema patients.
- CHAPTER-3 reported a favorable safety profile for once-daily deucrictibant XR in hereditary angioedema prophylaxis.
- Detailed CHAPTER-3 data will support planned NDA and global marketing submissions in the first half of 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.